

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Docket No.: RLL-544US

Serial No.: 10/596,059

Applicants: PALLE, *et al.*

Filed: April 16, 2007

Group: 1626

FEB 12 2009

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	S1A1	3,312,590	4/4/1967	Elks, et al.			
	S1A2	3,436,389	4/1/1969	Nathansohn, et al.	C07C	173/10	
	S1A3	3,506,694	4/14/1970	Oxley, et al.	C07C	169/34	
	S1A4	3,639,434	2/1/1972	Oxley, et al.	C07C	169/32	
	S1A5	3,642,896	2/15/1972	Collin, et al.	C07C	85/02	
	S1A6	3,644,353	2/22/1972	Lunts, et al.	C07D	87/40	
	S1A7	3,652,554	3/28/41972	Anner, et al.	C07C	169/28	
	S1A8	3,700,681	10/24/1972	Barth	C07D	31/42	
	S1A9	3,705,233	12/5/1972	Lunts, et al.	A61K	27/00	
	S1A10	3,721,687	3/20/1973	Elks, et al.	C07C	160/30	
	S1A11	3,780,177	12/18/197	Ercoli, et al.	A61K	17/00	
	S1A12	3,928,326	12/23/1975	Brattsand, et al.	C07J	17/00	
	S1A13	3,929,768	12/30/1975	Brattsand, et al.	C07J	17/00	
	S1A14	3,937,838	2/10/1976	Wetterlin, et al.	A61K	31/22	
	S1A15	3,947,478	3/30/1976	Woods, et al.	C07J	1/00	
	S1A16	3,980,778	9/14/1976	Ayer, et al.	A61K	31/56	
	S1A17	3,983,233	9/28/1976	Brattsand, et al.	C07J	17/00	
	S1A18	3,992,534	11/16/1976	Brattsand, et al.	C07J	17/00	
	S1A19	3,994,974	11/30/1976	Murakami, et al.	C07C	103/38	
	S1A20	4,011,258	3/8/1977	Wetterlin, et al.	C07C	93/26	
	S1A21	4,014,909	3/29/1977	Torossian, et al.	C07J	31/00	
	S1A22	4,076,708	2/28/1978	Green, et al.	C07J	71/00	
	S1A23	4,081,541	3/28/1978	Bertelli	A61K	31/56	
	S1A24	4,098,803	7/4/1978	Torossian, et al.	C07J	31/00	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1A25	4,115,589	9/19/1978	Lednicer	A01N	9/20	
	S1A26	4,124,707	11/7/1978	Green, et al.	C07J	5/00	
	S1A27	4,158,055	6/12/1979	Sultz, et al.	A61K	31/58	
	S1A28	4,226,862	10/7/1980	Riva, et al.	C07J	5/00	
	S1A29	4,242,334	12/30/1980	Stache, et al.	A61K	31/56	
	S1A30	4,290,962	9/22/1981	Tachi, et al.	C07D	5/00	
	S1A31	4,298,604	11/3/1981	Hammell	A61K	31/56	
	S1A32	4,335,121	6/15/1982	Phillipps, et al.	C07J	7/00	
	S1A33	4,419,364	12/6/1983	Olsson, et al.	A61K	31/27	
	S1A34	4,472,392	9/18/1984	Anderson, et al.	A61K	31/56	
	S1A35	4,472,393	9/18/1984	Shapiro	A61K	31/56	
	S1A36	4,579,985	4/1/1986	Minderhoud, et al.	C07C	1/04	
	S1A37	4,587,236	5/6/1986	Annen, et al.	A61K	31/56	
	S1A38	4,619,921	10/28/1986	Kalvoda, et al.	A61K	31/56	
	S1A39	4,780,469	10/25/1988	Toda, et al.	A61K	31/35	
	S1A40	4,826,868	5/2/1989	Wachter, et al.	A31K	31/415	
	S1A41	4,859,692	8/22/1989	Bernstein, et al.	A61K	31/40	
	S1A42	4,873,259	10/10/1989	Summer, Jr., et al.	A61K	31/38	
	S1A43	4,992,474	2/12/1991	Skidmore, et al.	A61K	31/135	
	S1A44	5,015,746	5/14/1991	Mizushima, et al.	A61K	31/56	
	S1A45	5,126,375	6/30/1992	Skidmore, et al.	A61K	31/135	
	S1A46	5,243,076	9/7/1993	Skidmore, et al.	A61K	31/135	
	S1A47	5,278,156	1/11/1994	Mizushima, et al.	A61K	31/56	
	S1A48	5,482,934	1/9/1996	Calatayud, et al.	A61K	31/58	
	S1A49	5,565,473	10/15/1996	Belley, et al.	A01N	43/42	
	S1A50	5,583,152	12/10/1996	Bernstein, et al.	A61K	31/40	
	S1A51	5,710,170	1/20/1998	Guay, et al.	C07D	213/30	

EXAMINER	DATE CONSIDERED
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1A52	5,712,298	1/27/1998	Amschler	C07D	213/75	
	S1A53	5,716,967	2/10/1998	Kleinman	C07D	261/04	
	S1A54	5,837,699	11/17/1998	Sequeira, et al.	A61K	31/56	
	S1A55	5,889,015	3/30/1999	Sequeira, et al.	A61K	31/58	
	S1A56	5,976,573	11/2/1999	Kim	A61K	9/14	
	S1A57	6,057,307	5/2/2000	Sequeira, et al.	A61K	31/56	
	S1A58	6,127,353	10/3/2000	Yuen, et al.	A61K	31/58	
	S1A59	6,180,781	1/30/2001	Yuen, et al.	C07J	17/00	
	S1A60	6,337,324	1/8/2002	Harmenberg, et al.	A61K	31/56	
	S1A61	6,723,713	4/20/2004	Sequeira, et al.	A61K	31/56	
	S1A62	7,183,321	2/27/2007	Li, et al.	A61K	31/155	
	S1A63	2005/0075383	4/7/2005	Palle, et al.	A61K	31/42	
	S1A64	2008/0009533	1/10/2008	Balachandran, et al.	A61K	31/424	
	S1A65	60/598,621	8/4/2004	Palle, et al.			
	S1A66	60/630,517	11/23/200	Palle, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	S1B1	EP 0 287 436	10/19/1988	EPO	C07D	257/02	NO
	S1B2	EP 0 387 941	9/19/1990	EPO	C07D	413/04	
	S1B3	EP 0 389 359	9/26/1990	EPO	C07D	257/02	NO
	S1B4	EP 0 419 049	12/4/1995	EPO	C07D	401/12	
	S1B5	EP 0 515 684	12/2/1992	EPO	A61K	31/10	
	S1B8	EP 0 542 355	5/19/1993	EPO	C07D	401/12	
	S1B8	EP 0 542 356	5/19/1993	EPO	C07D	401/12	
	S1B8	EP 0 988 292	2/12/2003	EPO	C07D	241/100	
	S1B9	IN 211/DEL/2005	2/2/2005	India			

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1B10	IN 1098/DEL/2005	5/3/2005	India			
	S1B11	JP 11-071319	3/16/1999	Japan	C07C	47/575	
	S1B12	WO 01/90106	11/29/2001	PCT	C07D	451/00	
	S1B13	WO 02/26723	4/4/2002	PCT	C07D	265/30	
	S1B14	WO 02/32898	4/25/2002	PCT	C07D	451/00	
	S1B15	WO 02/32899	4/25/2002	PCT	C07D	451/10	NO
	S1B16	WO 02/50070	6/27/2002	PCT	C07D	413/14	
	S1B17	WO 2005/021515	3/10/2005	PCT	C07D	261/04	
	S1B18	WO 2005/051931	6/9/2005	PCT	C07D	261/04	
	S1B19	WO 2006/085212	8/17/2006	PCT	C07D	498/10	
	S1B20	WO 2006/090234	8/31/2006	PCT	C07D	261/04	
	S1B21	WO 2006/122770	11/23/2006	PCT	C07D	498/10	NO
	S1B22	WO 2007/045979	4/26/2007	PCT	A61K	31/401	
	S1B23	WO 2007/045980	4/26/2007	PCT	A61K	31/41	
	S1B24	WO 2007/125984	11/8/2007	PCT	C07D	261/04	NO
	S1B25	WO 2008/035316	3/27/2008	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	S1C1	Zhang <i>et al.</i> , "Phosphodiesterase-4 as a potential drug target", <i>Expert Opinion on Therapeutic Targets</i> , 9(6):1283-1305 (2005)
	S1C2	Houslay <i>et al.</i> , "Keynote Review: Phosphodiesterase-4 as a therapeutic target", <i>Drug Discovery Today</i> , 10(22):1503-1519 (2005)
	S1C3	Lambrecht <i>et al.</i> , "Pharmacology of Hexahydro-difeniodol Hexahydro-sila-difeniodol and Related Selective Muscarinic Antagonists", <i>Trends in Pharmaceutical Sciences</i> , 10, 60-65 (1989)
	S1C4	Birdsall <i>et al.</i> , "Muscarinic Receptor Subclasses", <i>Trends in Pharmaceutical Sciences</i> , 4, 459-464 (1983)
	S1C5	Coruzzi, <i>et al.</i> , "Gastric Antisecretory Activity of Telenzepine, A New M ₁ - Selective Muscarinic Antagonist: Comparison with Pirenzepine", <i>Arch Int Pharmacodyn Ther</i> , 302, 232 - 241 (1989)
	S1C6	Kawashima <i>et al.</i> , "Pharmacological Differentiation of Presynaptic M ₁ Muscarinic Receptors Modulating Acetylcholine Release from Postsynaptic Muscarinic Receptors in guinea-Pig Ileum", <i>Gen. Pharma.</i> , 21(1), 17-21 (1990)
	S1C7	Burnouf <i>et al.</i> , "Synthesis, Structure-Activity Relationships, and Pharmacological Profile of 9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1- <i>h</i>]indoles: Discovery of Potent, Selective Phosphodiesterase Type 4 Inhibitors", <i>Journal of Medicinal Chemistry</i> , 43(25):4850-4867 (2000)

EXAMINER	DATE CONSIDERED
<p><small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small></p>	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

S1C8	Tian <i>et al.</i> , "1,3-Dipolar Cycloaddition Reactions of Nitrile Oxides to Prop-1-ene-1,3-sultone" <i>Journal of Heterocyclic Chemistry</i> , 40 (6):1071-1074 (2003)
S1C9	Salgado-Zamora <i>et al.</i> , "Oxidative degradation of arylfuro-1,2-oxazoles to aryl nitriles by potassium permanganate" <i>Heterocyclic Communications House</i> , 7 (3):209-212 (2001)
S1C10	Hassikou <i>et al.</i> , "Synthèse de nouveaux polyhétérocycles" <i>Tetrahedron Letters</i> , 42 (34):5857-5861 (2001)
S1C11	Syassi <i>et al.</i> , "Nouvelle méthode de synthèse des 4,5-dihydroisoxazoles en milieu biphasique solide-liquide et par activation ultrasonique" <i>Tetrahedron Letters</i> , 40 (40), 7250-7209 (1999)
S1C12	Subramanian <i>et al.</i> , "Facile Synthesis of 3-Aroyl-3-Sulfolenes Through Cycloadditions of Arylnitrile Oxides & 3-Sulfolene" <i>Synthetic Communications</i> , 27 (15):2557-2562 (1997)
S1C13	Brahmeshwari <i>et al.</i> , "Synthesis of 3-arylnaphth[2,3- <i>d</i>]-isoxazole-4, 9-diones from Lawsone", <i>Indian Journal of Chemistry, Section B</i> , 34B (2):139-140 (1995) - ABSTRACT ONLY
S1C14	Gaboury and Sibi, "Enantiocontrolled Synthesis of Burseran, Brassilignan, Dehydroxycubebin, and Other Tetrahydrofuran Lignans in Both Enantiomeric Forms. Application of Intermolecular Nitrile Oxide Cycloadditions and Lipase Mediated Kinetic Resolutions" <i>Journal of Organic Chemistry</i> , 58 (8):2173-2180 (1993)
S1C15	Brahmeshwari <i>et al.</i> , "Synthesis and Biological Activity of Fused Heterocycles Derived From Embelin" <i>Indian Journal of Chemistry, Section B</i> , 30B (3):369-370 (1991)) - ABSTRACT ONLY
S1C16	Awad and Sobhy, "1,3-Dipolar Cycloaddition of Nitrile Oxides. II. Reactions with o-quinoid Structures" <i>Canadian Journal of Chemistry</i> , 47 (9):1473-1477 (1969)
S1C17	Syassi <i>et al.</i> , "Addition Dipolaire-1,3 des Arylnitriloxydes avec quelques Dipolarophiles Oléfiniques sur Alumine en Milieu sec et sous Micro-ondes", <i>Tetrahedron Letters</i> , 38 (51):8855-8858 (1997)
S1C18	Descacq <i>et al.</i> , "Arylpyrazolines nitrofuraniques: synthèse et propriétés antibactériennes", <i>European Journal of Medicinal Chemistry</i> , 25 (3):285-290 (1990)
S1C19	Bisagni <i>et al.</i> , "Synthesis of 3-aryl-4-acetyl-1H-pyrazolo[3,4- <i>b</i>]pyridines and 3-aryl-4-acetyl-1H-pyrazolo[4,3- <i>c</i>]pyridines" <i>Heterocycles</i> , 29 (9):1815-1824 (1989)
S1C20	Haiza, "Synthesis of some new 3,5-bisaryl-2-pyrazoline derivatives of expected antimicrobial activities", <i>Al-Azhar Bulletin of Science</i> , 8 (2):445-454 (1997) - ABSTRACT ONLY
S1C21	Varache-Beranger <i>et al.</i> , "Thienylbenzofurans and Arylthienylpyrazolines: Synthesis and Inhibitory Effects on Platelet Aggregation in vitro", <i>Bulletin de la Societe de Pharmacie de Bordeaux</i> , 127 (1-2-3-4):37-48 (1988) - Abstract only
S1C22	Vanden Eynde and Mailleux, "Quaternary Ammonium Salt-Assisted Organic Reactions in Water: Alkylation of Phenols", <i>Synthetic Communications</i> , 31 (1):1-7, (2001)
S1C23	Guay <i>et al.</i> , "Discovery of L-791,943: A Potent, Selective, Non Emetic and Orally Active Phosphodiesterase-4 Inhibitor", <i>Bioorganic and Medicinal Chemistry Letters</i> , 12 (11):1457-1461 (2002)
S1C24	Chauret <i>et al.</i> , "Improving Metabolic Stability of Phosphodiesterase-4 Inhibitors Containing a Substituted Catechol: Prevention of Reactive Intermediate Formation and Covalent Binding", <i>Bioorganic and Medicinal Chemistry Letters</i> , 12 (16):2149-2152 (2002)
S1C25	Langlois, "Improvement of the Synthesis of Aryl Difluoromethyl Ethers and Thioethers by Using a Solid-Liquid Phase-Transfer Technique", <i>Journal of Fluorine Chemistry</i> , 41 (2):247-261 (1988)
S1C26	Raju <i>et al.</i> , "Conformationally Restricted Analogs of Deoxynegamycin", <i>Bioorganic and Medicinal Chemistry Letters</i> , 14 (12):3103-3107 (2004)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION	Docket No.: RLL-544US	Serial No.: 10/596,059
	Applicants: PALLE, <i>et al.</i>	
	Filed: April 16, 2007	Group: 1626

	S1C27	Vinick <i>et al.</i> , "An Efficient Synthesis of 1-Phenyl-1-Piperidino-trans-4-Methylcyclohexane: Unanticipated Total Stereoselectivity in the Catalytic Hydrogenation of an Olefin", <i>Tetrahedron Letters</i> , <u>28</u> (7):741-744 (1987)
	S1C28	King <i>et al.</i> , "(±) 3-Amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole: A Conformationally Restricted Analogue of 5-Carboxamidotryptamine with Selectivity for the Serotonin 5-HT _{1D} Receptor", <i>Journal of Medicinal Chemistry</i> , <u>36</u> (13):1918-1919 (1993)
	S1C29	Noguchi <i>et al.</i> , "Total Synthesis and Absolute Configuration of Radiosumin, a Strong Trypsin Inhibitor From the Blue-green Alga <i>Plectonema Radiosum</i> ", <i>Heterocycles</i> , <u>58</u> :471-504 (2002)
	S1C30	Shang <i>et al.</i> , "Diastereoselective Cycloadditions of a Soluble Polymer-supported Substituted Allyl Alcohol Derived From Baylis-Hillman Reaction with Nitrile Oxides", <i>Tetrahedron</i> , <u>64</u> (24):5779-5783 (2008) – ABSTRACT ONLY
	S1C31	Walters <i>et al.</i> , "The Preparation of 5-Aryl-5-methyl-4,5-dihydroisoxazoles From Dilithiated C(α),O-oximes and Select Acetyl Ketones", <i>Synthetic Communications</i> , <u>33</u> (23):4163-4171 (2003)
	S1C32	Vippagunta <i>et al.</i> , "Crystalline solids", <i>Advanced Drug Delivery Reviews</i> , <u>48</u> :3-26 (2000)
	S1C33	Chawla and Bansal, "Challenges in Polymorphism of Pharmaceuticals", <i>CRIPS</i> , <u>5</u> (1):9-12 (2004)
	S1C34	Newman and Byrn, "Solid-state Analysis of the Active Pharmaceutical Ingredient in Drug Products", <i>Drug Discovery Today</i> , <u>8</u> (19):898-905 (2003)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	